Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance
暂无分享,去创建一个
M. Cazzola | M. Paulli | L. Arcaini | M. Varettoni | V. Ferretti | L. Malcovati | A. Gallì | S. Zibellini | E. Boveri | I. Defrancesco | E. Rizzo | Chiara Candido | M. D. Porta
[1] S. Ferrero,et al. Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment , 2018, Current Treatment Options in Oncology.
[2] B. Quesnel,et al. TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia , 2017, Clinical Cancer Research.
[3] S. Treon,et al. To select or not to select? The role of B‐cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia , 2017, British journal of haematology.
[4] S. Treon,et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. , 2016, Blood.
[5] R. Advani,et al. Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström Macroglobulinaemia , 2016, British journal of haematology.
[6] S. Treon,et al. MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia. , 2015, The New England journal of medicine.
[7] L. Quintanilla‐Martinez,et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity , 2015, British journal of haematology.
[8] R. Advani,et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. , 2015, The New England journal of medicine.
[9] B. Quesnel,et al. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia , 2014, Clinical Cancer Research.
[10] A. Roccaro,et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. , 2014, Blood.
[11] S. Rodig,et al. The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia , 2014, Leukemia.
[12] Dereje D. Jima,et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. , 2014, Blood.
[13] S. Treon,et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. , 2014, Blood.
[14] S. Treon,et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. , 2014, Blood.
[15] M. Calaminici,et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.
[16] Manel Juan,et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[17] M. Cazzola,et al. MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. , 2013, Blood.
[18] N. Gray,et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. , 2013, Blood.
[19] M. Cazzola,et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. , 2013, Blood.
[20] N. Munshi,et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. , 2013, Blood.
[21] N. Gutiérrez,et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia , 2013, Leukemia.
[22] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[23] L. Staudt,et al. MYD88 L265P somatic mutation in IgM MGUS. , 2012, The New England journal of medicine.
[24] B. Quesnel,et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. , 2012, Blood.
[25] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.
[26] S. Pileri,et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development , 2012, The Journal of experimental medicine.
[27] T. Therneau,et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. , 2012, Blood.
[28] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[29] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[30] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[31] R. Pfeiffer,et al. Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. , 2010, Blood.
[32] S. Treon,et al. IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia , 2010, Haematologica.
[33] M. Björkholm,et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. , 2008, Blood.
[34] C. Morton,et al. Characterization of familial Waldenstrom's Macroglobulinemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] T. Therneau,et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. , 2003, Seminars in oncology.
[36] R. Gorlin,et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.
[37] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[38] J. Bernstein,et al. Defects of B-cell terminal differentiation in patients with type-1 Kabuki syndrome. , 2016, The Journal of allergy and clinical immunology.
[39] Claude-Alain H. Roten,et al. Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..